Mirtalich (Mirtazapine)

Mirtazapine, the active ingredient in Mirtalich, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as an oral formulation for oral use. It is prescribed for the treatment of major depressive disorder in adult patients, helping to improve mood, sleep and appetite when other therapies are insufficient.

GNH USA supplies Mirtalich as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. Our global distribution network facilitates reliable access to this essential psychiatric medication.

Mirtazapine is indicated for depressive disorders and works by modulating noradrenergic and serotonergic pathways.

- Major depressive disorder: alleviates depressive symptoms and improves overall mood. - Depression with insomnia: helps normalize sleep patterns. - Depression‑related anxiety: reduces anxiety and agitation associated with depressive episodes.

Common Side Effects: - Sedation - Increased appetite - Dry mouth - Constipation

Serious or Rare Side Effects: - Agranulocytosis - Seizures - Severe hypotension

Before initiating therapy, consider the following precautions: - Assess hepatic function: evaluate liver enzymes prior to treatment. - Monitor blood pressure: watch for orthostatic hypotension, especially during dose escalation. - Screen for suicidal ideation: assess risk in all patients with depressive disorders. - Use caution in elderly: increased sensitivity to sedation and fall risk. - Avoid abrupt discontinuation: taper under medical supervision. - Store at room temperature: keep in the original container, protect from moisture.

Mirtazapine may interact with several medicines. Review the following groups:

Major Interactions (Avoid): - MAO inhibitors: concurrent use can cause hypertensive crisis. - Other serotonergic agents (e.g., SSRIs, SNRIs, tramadol): risk of serotonin syndrome.

Moderate Interactions (Monitor Closely): - CNS depressants (e.g., benzodiazepines): additive sedation. - Antihypertensives: may enhance hypotensive effect. - CYP3A4 inhibitors (e.g., ketoconazole): increase mirtazapine plasma levels.